Patents Issued in June 21, 2018
  • Publication number: 20180170942
    Abstract: Contemplated compounds, compositions and methods are directed to Ral GTPase inhibitors with improved activity.
    Type: Application
    Filed: June 16, 2016
    Publication date: June 21, 2018
    Inventors: Chunlin Tao, Chengzhi Yu, Tulay Polat, Chao Yan, Shahrooz Rabizadeh, Daniel Theodorescu
  • Publication number: 20180170943
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 21, 2018
    Inventors: Shanghai YU, Fanglong YANG, Lei CHEN, Jingjing YAN, Xiqian ZHANG, Zhichao XIE, Lingxiang CHEN, Mingxun HE
  • Publication number: 20180170944
    Abstract: Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues.
    Type: Application
    Filed: March 24, 2015
    Publication date: June 21, 2018
    Applicant: Canget BioTekpharma, LLC
    Inventors: Fengzhi LI, Xiang LING
  • Publication number: 20180170945
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Application
    Filed: October 25, 2017
    Publication date: June 21, 2018
    Inventors: Chiajen Lai, Bing Shi
  • Publication number: 20180170946
    Abstract: The invention provides protein tyrosine phosphatase inhibitor compounds, Their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5).
    Type: Application
    Filed: June 16, 2016
    Publication date: June 21, 2018
    Inventors: John S. Lazo, Elizabeth R. Sharlow, Kelley E. McQueeney, Peter Wipf, Joseph M. Salamoun
  • Publication number: 20180170947
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
    Type: Application
    Filed: June 22, 2016
    Publication date: June 21, 2018
    Inventors: Zoltan SZLAVIK, András KOTSCHY, Maïa CHANRION, Didier DEMARLES, Olivier GENESTE, James Edward Paul DAVIDSON, James Brooke MURRAY, Szabolcs SIPOS, Attila PACZAL, Balazs BALINT
  • Publication number: 20180170948
    Abstract: The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1?, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 21, 2018
    Inventors: Kyle W.H. Chan, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan, Eduardo Torres
  • Publication number: 20180170949
    Abstract: Described herein are methods for the manufacture of ceftolozane and related compounds, as well as compositions comprising the same.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 21, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Kristos Adrian MOSHOS, Valdas JURKAUSKAS, Giovanni FOGLIATO, Manuel SCANU, Michele BENOTTI
  • Publication number: 20180170950
    Abstract: Aluminum chloride is separated from a silane mixture containing aluminum chloride by reacting the aluminum chloride with a compound reactive therewith which forms an ionic liquid or solid, and separating the ionic liquid or solid from the now-purified silane.
    Type: Application
    Filed: April 3, 2017
    Publication date: June 21, 2018
    Applicant: Wacker Chemie AG
    Inventors: Andreas BOCKHOLT, Konrad MAUTNER
  • Publication number: 20180170951
    Abstract: The present invention relates to conjugate compounds and methods of making and using same.
    Type: Application
    Filed: June 13, 2016
    Publication date: June 21, 2018
    Inventors: Marion THÉVENIN, Robert N. YOUNG, Gang CHEN
  • Publication number: 20180170952
    Abstract: The present invention provides a method for preparing rhodium (III) 2-ethylhexanoate solutions which supplies the reaction product with higher space yield, as well as lower sodium and chloride ion content. An aqueous solution of an alkali salt of 2-ethylhexanoate is thereby initially converted with a rhodium (III) precursor. The rhodium (III) precursor is selected from rhodium (III) chloride solution, rhodium (III) chloride hydrate, and rhodium (III) nitrate. The mixture is heated for several hours. After cooling to room temperature, the rhodium (III) 2-ethylhexanoate formed is extracted from the aqueous solution with an alcohol that is immiscible in water or a carboxylic acid that is immiscible in water, and optionally washed with aqueous mineral acid. The rhodium (III) 2-ethylhexanoate solution obtainable in this way may be used directly as catalyst in hydroformylation reactions.
    Type: Application
    Filed: July 1, 2016
    Publication date: June 21, 2018
    Inventors: Angelino DOPPIU, Birgit EMRICH, Ralf KARCH, Andreas RIVAS-NASS, Eileen WOERNER
  • Publication number: 20180170953
    Abstract: The present invention relates to a theranostic system comprising a beacon and a compound selected from the group consisting of a quinazoline-based tyrosine kinase inhibitor and a natural product. The theranostic systems have use in the therapy and diagnosis of tyrosine kinase related malignancies.
    Type: Application
    Filed: January 10, 2018
    Publication date: June 21, 2018
    Inventors: Andreani ODYSSEOS, Costas PITRIS, Anastasios KERAMIDAS
  • Publication number: 20180170954
    Abstract: The present invention relates to improved processes for the preparation of ruthenium or osmium complexes comprising P and N donor ligands, in particular, ruthenium complexes.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Inventors: Sarah FACCHETTI, Hans NEDDEN
  • Publication number: 20180170955
    Abstract: A compound of formula I: or a salt thereof, wherein: R1 is —OC(H)(X)(CH2)nC(?O)OH; R2 is —OH, —N3, or —N(H)C(?O)CH3; or R1 and R2 together with the carbon atoms to which they are attached form R3 is —H, —CH3, —CH2C(?O)OH, or —CH2OH; X is —H, —CH3, —CH2OH, or CH2C(?O)OH; and n is 0 or 1.
    Type: Application
    Filed: March 13, 2015
    Publication date: June 21, 2018
    Inventors: Christopher David Maycock, Maria Rita Mendes Bordalo Ventura Centeno Lima, Eva Correia Lourenço, Maria Helena Dias Dos Santos, Ana Sofia Da Cunha Miguel
  • Publication number: 20180170956
    Abstract: A process for preparing a composition (C1) represented by the formula (I): HO—CH2—(CHOH)n—CH2—O-(G)x-H, in which G represents the remainder of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of the remainder G, represents a decimal number greater than 1 and less than or equal to 5, characterized in that the process includes at least one step a) of reacting a polyol of formula (A1): HO—CH2—(CHOH)n—CH2—OH, in which n is an integer equal to 2, 3 or 4, with a reducing sugar of formula (II): HO-G-H, in which G represents the remainder of a reducing sugar, in the presence of an acid catalyst (Ca), and in that the acid catalyst (Ca) is chosen from phosphorous acid, phosphoric acid and polyphosphoric acid.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 21, 2018
    Inventors: Andre BENATTAR, Andrey BONNARDEL, Jerome GUILBOT, Sebastien KERVERDO, Herve ROLLAND, Guy TABACCHI
  • Publication number: 20180170957
    Abstract: Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.
    Type: Application
    Filed: January 9, 2018
    Publication date: June 21, 2018
    Inventors: Chi-Huey WONG, Alice L. YU, Kun-Hsien LIN, Tai-Na WU
  • Publication number: 20180170958
    Abstract: The present invention relates to crystalline Form A of obeticholic acid and the preparation method thereof. The present invention provides Form A having characteristic peaks at 2theta value of 4.9°±0.2°, 5.2°±0.2°, 9.9°±0.2°. The present invention provides a novel crystalline form of obeticholic acid, which has good stability, good processability and other favorable properties, and is suitable for storage and usage as a final product. In addition, the preparation method is simple, low cost, and has great value for the future optimization and development of obeticholic acid.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 21, 2018
    Applicant: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan Diao, Xiaoyu Zhang
  • Publication number: 20180170959
    Abstract: The invention provides a method of efficiently and stably producing ?-form crystal of reduced glutathione, and a preservation method thereof. According to the invention, development of ?-form crystal and/or transition to ?-form crystal of reduced glutathione are suppressed by the coexistence of at least one kind of compound selected from the group of aliphatic amino acid, sulfur-containing amino acid, aromatic amino acid, an analogous compound and dipeptide, as a habit modifier, during production and preservation of an aqueous solution or ?-form crystal of reduced glutathione.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 21, 2018
    Applicant: KYOWA HAKKO BIO CO., LTD.
    Inventors: Maya IGUCHI, Kazunari FUKUMOTO, Hiroshi NAGANO
  • Publication number: 20180170960
    Abstract: A method for expressing, as a soluble protein or an active-form mutant enzyme, an enzyme that cannot be expressed as a soluble protein or an active-form enzyme in a heterologous expression system or that is obtained in a minute amount even when an active-form enzyme is expressed, the method including a technique for selecting an effective mutation site and a mutated amino acid. A new active-form mutant enzyme is also disclosed. The method involves: specifying an insoluble protein or an inactive-form enzyme; specifying a hydrophilic amino acid in a hydrophobic domain and/or a hydrophobic amino acid in a hydrophilic domain of an ?-helix structure portion of the insoluble protein or the inactive-form enzyme and preparing a gene that codes for an amino acid sequence in which a substitution is made to the hydrophilic amino acid in the hydrophobic domain and/or the hydrophobic amino acid in the hydrophilic domain.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Applicant: Toyama Prefectural University
    Inventors: Yasuhisa Asano, Daisuke Matsui, Yuko Oku
  • Publication number: 20180170961
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Application
    Filed: December 28, 2017
    Publication date: June 21, 2018
    Applicants: University-Industry Cooperation Group of Kyung Hee University, Industry-Academic Cooperation Foundation Gyeongsang National University
    Inventors: Se-Young CHOUNG, Yeung Joon CHOI
  • Publication number: 20180170962
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Inventors: Mark S. Smyth, Guy J. Laidig
  • Publication number: 20180170963
    Abstract: Provided are a conotoxin peptide ?-CPTx-btl04 and a derivative polypeptide. The amino acid sequence of the conotoxin peptide is indicated by SEQ ID NO: 1. Also provided are a conotoxin peptide preparation method and uses of the conotoxin peptide in the treatment of diseases related to a calcium ion channel.
    Type: Application
    Filed: December 26, 2014
    Publication date: June 21, 2018
    Inventors: Jie LIU, Zhilong LIN, Bo WEN, Ting TONG, Fen MO, Chao PENG, Qiong SHI
  • Publication number: 20180170964
    Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 21, 2018
    Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
  • Publication number: 20180170965
    Abstract: An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative (?) bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 23 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.
    Type: Application
    Filed: May 25, 2016
    Publication date: June 21, 2018
    Inventors: Yong Ae Kim, Ji Sun Kim, Ji Ho Jeong
  • Publication number: 20180170966
    Abstract: The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-?B and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN).
    Type: Application
    Filed: January 19, 2018
    Publication date: June 21, 2018
    Inventors: Yong-Ji CHUNG, Eun-Mi KIM, Eung-Ji LEE, Tae-Hoon LEE, A-Reum HAN
  • Publication number: 20180170967
    Abstract: Cyclized peptides derived from the hyaluronan binding region of RHAMM are provided. Pharmaceutical compositions and methods for using the peptides and pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 21, 2016
    Publication date: June 21, 2018
    Inventors: Leonard Luyt, Eva Turley, Alexandra Hauser-Kawaguchi, Emily Rodrigues
  • Publication number: 20180170968
    Abstract: The present invention relates to methods of improving the environment within a poultry farming facility including reducing ammonia production in a poultry facility, inhibiting urease enzymes in poultry litter, reducing levels of pathogenic bacteria in poultry litter, improving productivity of poultry farms, reducing or preventing pododermatitis in poultry reared in mass production poultry facilities and controlling pests in poultry litter. Compositions, suitable for use in such methods, comprising at least one microorganism of the genus Bacillus and at least one biosurfactant wherein the biosurfactant is present in an amount of 2 mg/L to 7000 mg/L are also described.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 21, 2018
    Inventors: Michael Paul Bralkowski, Sarah Ashley Brooks, Stephen M. Hinton, David Matthew Wright, Shih-Hsin Yang
  • Publication number: 20180170969
    Abstract: A multipartite peptide that inhibits release of exosomes in a cell, comprising an N-terminal end and a C-terminal end and comprising at least one secretion modifying region (SMR) peptide from HIV-1 Nef and at least one Clusterin (Clu)-binding peptide (Clu-BP). Pharmaceutical compositions comprising these peptides alone or in synergistic combinations with other active agents in methods for treating cancers and/or infectious diseases are further provided herein.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 21, 2018
    Inventors: Vincent C. BOND, James W. Lillard, JR., Ming Bo Huang
  • Publication number: 20180170970
    Abstract: The present invention relates to a chimeric virus particle of potato virus X, said particle having, as a capsid protein, a fusion protein containing a capsid protein and an antigenic determinant of lipocalin, and the use thereof in the in vitro diagnosis of Sjögren's Syndrome using the ELISA method.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 21, 2018
    Inventors: Chiara LICO, Selene BASCHIERI, Eugenio BENVENUTO, Linda AVESANI, Elisa TINAZZI, Elena BARTOLONI BOCCI, Mario PEZZOTTI, Claudio LUNARDI
  • Publication number: 20180170971
    Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.
    Type: Application
    Filed: September 28, 2017
    Publication date: June 21, 2018
    Inventors: Christian BRANDER, Beatriz MOTHE PUJADAS, Anuska LLANO
  • Publication number: 20180170972
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra Franz VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20180170973
    Abstract: A protein includes two or more amino acid sequences, wherein each amino acid sequence is derived from a sequence selected from the group consisting of SEQ ID NOs:1 to 5. The amino acid sequence closest to the N-terminus includes a substitution of an amino acid residue at a position corresponding to position 4 or 7 of SEQ ID NO: 5 with an amino acid residue other than Arg, and productivity of the protein in a transformant producing the protein is improved, as compared to productivity of a protein including the amino acid sequence without the substitution.
    Type: Application
    Filed: February 2, 2018
    Publication date: June 21, 2018
    Applicant: Kaneka Corporation
    Inventors: Masakatsu Nishihachijyo, Keita Yamashita, Osamu Odawara, Takeyuki Tsuchidate, Masayuki Takano, Shinichi Yoshida
  • Publication number: 20180170974
    Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.
    Type: Application
    Filed: July 8, 2016
    Publication date: June 21, 2018
    Inventors: Bengt GUSS, Lars FRYKBERG, Margareta FLOCK, Jan-Ingmar FLOCK, Karl Olov ZACHRISSON
  • Publication number: 20180170975
    Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
    Type: Application
    Filed: November 16, 2017
    Publication date: June 21, 2018
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. REED, Rhea N. COLER, Gregory C. IRETON, Sylvie BERTHOLET
  • Publication number: 20180170976
    Abstract: The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 21, 2018
    Inventors: Jacqueline E. Heard, Jose Luis Riechmann, Robert A. Creelman, Oliver J. Ratcliffe, Roger D. Canales, Peter P. Repetti, Roderick W. Kumimoto, Neal I. Gutterson, T. Lynne Reuber, Omaira Pineda, Cai-Zhong Jiang, Karen S. Century, Luc Adam, James Z Zhang, Frederick D. Hempel, Jeffrey M. Libby
  • Publication number: 20180170977
    Abstract: A recombinant fusion protein is comprising a spider silk fragment and a cyclic RGD cell-binding motif with selectivity for integrins, such as for ?5?1 integrins. The fusion protein is useful as a cell scaffold material and for the cultivation of cells displaying integrins on their cell surface.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 21, 2018
    Applicant: Spiber Technologies AB
    Inventor: My Hedhammar
  • Publication number: 20180170978
    Abstract: The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 21, 2018
    Inventors: Horst ROSE, Dania Birte REICHE, Harald TAMMEN
  • Publication number: 20180170979
    Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 21, 2018
    Inventors: Pei-Tzu WU, Jia-Hau SHIU, Madhu CHERUKURY, Tan NGUYEN, Kevin ZEN
  • Publication number: 20180170980
    Abstract: The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing cancer, which comprises the polypeptide, and a method for preventing or treating cancer, which comprises administering the composition for treating or preventing cancer, which comprises the polypeptide. The disclosed polypeptide is capable of binding to vascular endothelial growth factor to inhibit the activity thereof, and thus can be widely used as an agent for treating and preventing various diseases associated with vascular endothelial growth factor (VEGF).
    Type: Application
    Filed: September 16, 2015
    Publication date: June 21, 2018
    Inventors: Hak-Sung Kim, Da Eun Hwang, Jeong Hyun Ryou
  • Publication number: 20180170981
    Abstract: The invention provides a recombinant polypeptide X—Y for enhancing cell transduction efficiency of a target agent, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Also provided is a method for enhancing cell transduction efficiency of a target agent, comprising conjugating/attaching said target agent with a recombinant polypeptide X—Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Further provided is a pharmaceutical composition comprising a therapeutic agent, wherein said therapeutic agent is modified by conjugating/attaching with a recombinant polypeptide X—Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 21, 2018
    Inventors: CHIN-KAI CHUANG, YU-HSIU SU, TZUYIN LIN
  • Publication number: 20180170982
    Abstract: The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and indentified formulations for research and therapeutic purposes.
    Type: Application
    Filed: July 12, 2017
    Publication date: June 21, 2018
    Applicant: BioTime, Inc.
    Inventors: Michael D. West, Karen B. Chapman
  • Publication number: 20180170983
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun N-terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the prevention and/or treatment of Mild Cognitive Impairment, in particular of Mild Cognitive Impairment due to Alzheimer's Disease.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 21, 2018
    Inventors: Jean-Marc Combette, Catherine Deloche
  • Publication number: 20180170984
    Abstract: Materials and methods for using modified Cas9-APOBEC fusion polypeptides for targeted modification of specific DNA sequences are provided herein.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 21, 2018
    Inventors: Reuben S. Harris, Hideki Aihara
  • Publication number: 20180170985
    Abstract: Methods and products (e.g., gRNAs, recombinant fusion proteins, frataxin targeting systems, compositions and kits) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 21, 2018
    Inventors: JACQUES P. TREMBLAY, PIERRE CHAPDELAINE, JOÈL ROUSSEAU
  • Publication number: 20180170986
    Abstract: The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 21, 2018
    Inventor: Haruo Sugiyama
  • Publication number: 20180170987
    Abstract: The disclosure features, among other things, polypeptides comprising a Cryptic polypeptide, a functional fragment thereof, or variants of any of the foregoing. Also featured are nucleic acids encoding the polypeptides, methods for producing of the polypeptides, and a variety of diagnostic and therapeutic applications in which the polypeptides are useful. For example, the polypeptides can be used to treat a subject having a condition associated with bone loss.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 21, 2018
    Inventors: Erik Martinez-Hackert, Senem Aykul
  • Publication number: 20180170988
    Abstract: The invention relates to truncated BMP-7 growth factors and variants thereof. The invention also relate to methods of making and using the truncated BMP-7 growth factors.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 21, 2018
    Applicant: LifeNet Health
    Inventors: Xiaofei QIN, Silvia Chen, Jingsong Chen, James Clagett
  • Publication number: 20180170989
    Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 21, 2018
    Inventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
  • Publication number: 20180170990
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 21, 2018
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD, Ron WEISS, Kristy M. WOOD
  • Publication number: 20180170991
    Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal ammo group of the peptide moiety B, or a salt thereof, or a hydrate thereof.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 21, 2018
    Inventors: Kazuo Kitamura, Johji KATO, Keishi KUBO, Kenji KUWASAKO, Shigeru KUBO, Kumiko KUMAGAYE